UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-11, Vol.379 (21), p.2027-2039

2018

Volltextzugriff (PDF)

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials

Journal of clinical oncology, 2018-09, Vol.36 (26), p.2693-2701

2018

Volltextzugriff (PDF)

Design of ALTA-1L (ALK in lung cancer trial of brigatinib in first-line), a randomized phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS9098-TPS9098

2017

Volltextzugriff (PDF)

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase

Blood, 2019-11, Vol.134 (Supplement_1), p.1567-1567

2019

Volltextzugriff (PDF)

Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L

Annals of oncology, 2019-10, Vol.30, p.vi83

2019

Volltextzugriff (PDF)

Brigatinib (BRG) in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Updates from a phase 1/2 trial

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e20682-e20682

2017

Volltextzugriff (PDF)

Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.9065-9065

2017

Volltextzugriff (PDF)

Spiritual care needs of hospitalized children and their families: a national survey of pastoral care providers' perceptions

Pediatrics (Evanston), 2003-01, Vol.111 (1), p.e67

2003

Volltextzugriff (PDF)

OA08.06 Brigatinib Activity in Patients with ALK+ NSCLC and Intracranial CNS Metastases in Two Clinical Trials

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S273-S274

2017

Volltextzugriff (PDF)

O1-4-2 [Encore]Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L

Annals of oncology, 2019-10, Vol.30 (Supplement_6)

2019

Volltextzugriff (PDF)

Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts

Archives of dermatology (1960), 2003-12, Vol.139 (12), p.1563

2003

Volltextzugriff (PDF)

The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking Vaccines

Infection and immunity, 2017-02, Vol.85 (2)

2017

Volltextzugriff (PDF)

Loss of the RhoGAP SRGP-1 promotes the clearance of dead and injured cells in Caenorhabditis elegans

Nature cell biology, 2011-01, Vol.13 (1), p.79

2011

Volltextzugriff (PDF)

Characteristics of thunder and electromagnetic pulses from volcanic lightning at Bogoslof volcano, Alaska

Bulletin of volcanology, 2020-02, Vol.82 (2), Article 15

2020

Volltextzugriff (PDF)

Short-Term Forecasting and Detection of Explosions During the 2016–2017 Eruption of Bogoslof Volcano, Alaska

Frontiers in earth science (Lausanne), 2018-09, Vol.6

2018

Volltextzugriff (PDF)

Development of Sediment and Nutrient Export Coefficients for U.S. Ecoregions

Journal of the American Water Resources Association, 2015-06, Vol.51 (3), p.758-775

2015

Volltextzugriff (PDF)

The Pediatrician’s Role in Preventing Child Maltreatment: Clinical Report

Pediatrics (Evanston), 2024-08, Vol.154 (2), p.1

2024

Volltextzugriff (PDF)

Child Fatality Review

Pediatrics (Evanston), 2024-03, Vol.153 (3), p.1

2024

Volltextzugriff (PDF)

Regional Blue and Green Water Balances and Use by Selected Crops in the U.S

Journal of the American Water Resources Association, 2015-12, Vol.51 (6), p.1626-1642

2015

Volltextzugriff (PDF)

Development of a Hydrologic Connectivity Dataset for SWAT Assessments in the US

Water (Basel), 2017-11, Vol.9 (11), p.892

2017

Volltextzugriff (PDF)

MP46-06 COMPARISON OF ADJUVANT RADIATION THERAPY BEFORE OR AFTER ARTIFICIAL URINARY SPHINCTER PLACEMENT: A MULTI-INSTITUTIONAL ANALYSIS

The Journal of urology, 2017-04, Vol.197 (4), p.e621-e621

2017

Volltextzugriff (PDF)

NEW GOURNA: CONSERVATION AND COMMUNITY

Traditional dwellings and settlements review, 2014-10, Vol.26 (1), p.85-85

2014

Volltextzugriff (PDF)

Mapping tumor growth rates in patients with malignant gliomas: A test of two algorithms

NeuroImage (Orlando, Fla.), 2000-05, Vol.11 (5), p.S905-S905

2000

Volltextzugriff (PDF)

Supervised Machine Learning

An Introduction to High Content Screening, 2014, p.231-245

2014

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(25)

Publikationsform

Sprache

Englisch
(30)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials

Design of ALTA-1L (ALK in lung cancer trial of brigatinib in first-line), a randomized phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase

Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L

Brigatinib (BRG) in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Updates from a phase 1/2 trial

Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status

Spiritual care needs of hospitalized children and their families: a national survey of pastoral care providers' perceptions

OA08.06 Brigatinib Activity in Patients with ALK+ NSCLC and Intracranial CNS Metastases in Two Clinical Trials

O1-4-2 [Encore]Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L

Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts

The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking Vaccines

Loss of the RhoGAP SRGP-1 promotes the clearance of dead and injured cells in Caenorhabditis elegans

Characteristics of thunder and electromagnetic pulses from volcanic lightning at Bogoslof volcano, Alaska

Short-Term Forecasting and Detection of Explosions During the 2016–2017 Eruption of Bogoslof Volcano, Alaska

Development of Sediment and Nutrient Export Coefficients for U.S. Ecoregions

The Pediatrician’s Role in Preventing Child Maltreatment: Clinical Report

Child Fatality Review

Turnout: Mobilizing Voters in an Emergency

Regional Blue and Green Water Balances and Use by Selected Crops in the U.S

Development of a Hydrologic Connectivity Dataset for SWAT Assessments in the US

MP46-06 COMPARISON OF ADJUVANT RADIATION THERAPY BEFORE OR AFTER ARTIFICIAL URINARY SPHINCTER PLACEMENT: A MULTI-INSTITUTIONAL ANALYSIS

NEW GOURNA: CONSERVATION AND COMMUNITY

Mapping tumor growth rates in patients with malignant gliomas: A test of two algorithms

Supervised Machine Learning

Suchergebnisse filtern